The German Research Network on Schizophrenia - Impact on the management of schizophrenia

Dialogues in Clinical Neuroscience

Volumn 8, Issue 1, 2006, Pages 115-121

  Wölwer, Wolfgang ^a   Baumann, Anja ^a   Bechdolf, Andreas ^d   Buchkremer, Gerhard ^b   Häfner, Heinz ^c   Janssen, Birgit ^a   Klosterkötter, Joachim ^d   Maier, Wolfgang ^e   Möller, Hans Jürgen ^f   Ruhrmann, Stephan ^d   Gaebel, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cognitive remediation; Destigmatization; Early intervention; Long term treatment; Quality assurance; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; LORAZEPAM; NEUROLEPTIC AGENT;

ARTICLE; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; GERMANY; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; PSYCHOSIS; RECOGNITION; SCHIZOPHRENIA; SOCIAL DISABILITY; WEIGHT GAIN;

COGNITION DISORDERS; COMMUNITY NETWORKS; COOPERATIVE BEHAVIOR; GERMANY; HEALTH PLANNING ORGANIZATIONS; HUMANS; RESEARCH; RESEARCH SUPPORT; RISK; SCHIZOPHRENIA;

EID: 33646146719     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wölwer W, Buchkremer G, Häfner H, et al. German Research Network on Schizophrenia - bridging the gap between research and care. Eur Arch Psychiat Clin Neurosc. 2003;253:321-329.
2. Häfner H, Maurer K, Löffler W, et al. The ABC schizophrenia study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33:380-386.
3. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23:3-9.
4. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. Br J Psychiatry. 1998;172(suppl 33):S14-S28.
5. Bottlender R, Sato T, Jager M, et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res. 2003;62:37-44.
6. Bottlender R, Möller HJ. The impact of the duration of untreated psychosis on the short- and longterm outcome in schizophrenia. Curr Opin Psychiatry. 2003;16 (suppl 2):39-43.
7. Häfner H, Maurer K, Ruhrmann S, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci. 2004:254:117-128.
8. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158-164.
9. Bechdolf A, Ruhrmann S, Wagner M, et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. Br J Psychiatry. 2005;187(suppl):s45-s48.
10. Bechdolf A, Veith V, Schwarzer D, et al. Cognitive-behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Res. 2005;136:251-255.
11. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkotter J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry. 2005;20:1-6.
12. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
13. Leucht St, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222.
14. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ. 2000;321:1371-1376.
15. Davis, JM, Chen, N, Click, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
16. Leucht St, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
17. Koponen H, Saari K, Savolainen M, Isohanni M. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. Eur Arch Psychiatry Clin Neurosci. 2002;252:294-298.
18. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002;28:5-16.
19. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
20. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No. 43. 2002.
21. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;CD000440.
22. Geddes J. Prevention of relapse in schizophrenia. N Engl J Med. 2002;346:56-58.
23. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.
24. Fleischhacker WW, Keet IP, Kahn RS. EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78:147-156.
25. Sheitman BB, Lee H, Strauss R, Lieberman J. The evaluation and treatment of first - episode psychosis. Schizophr Bull. 1997;23:653-661.
26. Wyatt RJ, Damiani M, Henter I. First episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry. 1998;172(suppl 33):77-83.
27. American Psychiatric Association: Practice Guidelines for the treatment of patients with schizophrenia. Am J Psychiatry. 1997; 154 (suppl 4):1-63.
28. Gaebel W, Falkai P, eds. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinie Schizophrenie. Darmstadt, Germany: Steinkopff; 2005.
29. Gaebel W, Moller HJ, Buchkremer G, et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254:129-140.
30. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156:299-303.
31. Edwards J, Jackson HJ, Pattison PE. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin Psychol Rev. 2002;22:789-832.
32. Edwards J, Pattison PE, Jackson HJ, Wales RJ. Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res. 2001;48:235-253.
33. Kee KS, Horan WP, Mintz J, Green MF. Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res. 2004;67:87-94.
34. Hooker C, Park S. Emotion processing and its relationship to social functioning in schizophrenia patients. Psychiatry Res. 2002;112:41-50.
35. Kee KS, Green MF, Mintz J, Brekke JS. Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull. 2003;29:487-497.
36. Kohler CG, Bilker W, Hagendoorn M, Gur RE, Gur RC. Emotion recognition deficit in schizophrenia: Association with symptomatology and cognition. Biol Psychiatry. 2000;48:127-136.
37. Wölwer W, Streit M, Polzer U, Gaebel W. Facial affect recognition in the course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1996;246:165-170.
38. Frommann N, Streit M, Wölwer W. Remediation of facial affect recognition impairments in patients with schizophrenia: a new training program. Psychiatry Res. 2003;117:281-284.
39. Wölwer W, Frommann N, Halfmann S, Piaszek A, Streit M, Gaebel W. Remediation of impairments in facial affect recognition in schizophrenia: Efficacy and specificity of a new training program. Schizophr Res. 2005;80:295-303.
40. Gmür M, Tschopp A Die Behandlungskontinuität bei schizophrenen Patienten in der Ambulanz. Eine 5-Jahres Untersuchung. Nervenarzt. 1988;59:727-730
41. Lehmann AF, Steinwachs DM Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-20.
42. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342:1317-1322.
43. Janssen B, Weinmann S, Berger M, et al. Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison. [in German]. Nervenarzt. 2005;76:315-326.
44. Janssen B, Menke R, Pourhassan F, Gessner-Ozokyay D, Peters R, Gaebel W. Guidelines based on decision support software. [In German]. Nervenarzt. 2005 [Epub ahead of print].
45. WPA. Global Programme Against Stigma and Discrimination Because of Schizophrenia. Chicago, III: Closer Look Creative, Inc; 1999.
46. Gaebel W, Baumann AE. Interventions to reduce the stigma associated with severe mental illness: experiences from the open the doors program in Germany. Can J Psychiatry. 2003;48:657-662.
47. Gaebel W, Baumann A, Witte AM, Zaeske H. Public attitudes towards people with mental illness in six German cities: results of a public survey under special consideration of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2002;252:278-287.